REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 152 filers reported holding REATA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 3.61 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,313,430 | -40.2% | 14,446 | -75.0% | 0.19% | -44.9% |
| Q4 2022 | $2,195,024 | +51.2% | 57,779 | 0.0% | 0.34% | +38.6% |
| Q3 2022 | $1,452,000 | +16.5% | 57,779 | 0.0% | 0.25% | +28.4% |
| Q2 2022 | $1,246,000 | -20.0% | 57,779 | +21.5% | 0.19% | -17.1% |
| Q1 2022 | $1,558,000 | +24.2% | 47,572 | +0.0% | 0.23% | +66.0% |
| Q4 2021 | $1,254,000 | -87.2% | 47,557 | -51.0% | 0.14% | -88.8% |
| Q3 2021 | $9,767,000 | -29.4% | 97,074 | -0.7% | 1.26% | -18.0% |
| Q2 2021 | $13,831,000 | +29.1% | 97,723 | -9.1% | 1.54% | +47.6% |
| Q1 2021 | $10,714,000 | -23.4% | 107,459 | -5.0% | 1.04% | -16.2% |
| Q4 2020 | $13,987,000 | +19.4% | 113,149 | -5.9% | 1.25% | +17.1% |
| Q3 2020 | $11,716,000 | -35.9% | 120,261 | +2.7% | 1.06% | -43.7% |
| Q2 2020 | $18,277,000 | +10.4% | 117,147 | +2.2% | 1.89% | -11.6% |
| Q1 2020 | $16,550,000 | -28.6% | 114,657 | +1.2% | 2.14% | -15.0% |
| Q4 2019 | $23,165,000 | +217.9% | 113,313 | +24.8% | 2.52% | +182.9% |
| Q3 2019 | $7,287,000 | -4.6% | 90,761 | +12.1% | 0.89% | +1.9% |
| Q2 2019 | $7,638,000 | +10.4% | 80,951 | 0.0% | 0.87% | +9.3% |
| Q1 2019 | $6,919,000 | +48.9% | 80,951 | -2.3% | 0.80% | +27.0% |
| Q4 2018 | $4,648,000 | -28.1% | 82,851 | +4.8% | 0.63% | -21.7% |
| Q3 2018 | $6,465,000 | +133.8% | 79,071 | 0.0% | 0.80% | +118.2% |
| Q2 2018 | $2,765,000 | +70.5% | 79,071 | 0.0% | 0.37% | +65.8% |
| Q1 2018 | $1,622,000 | -27.6% | 79,071 | 0.0% | 0.22% | -28.4% |
| Q4 2017 | $2,239,000 | -8.9% | 79,071 | 0.0% | 0.31% | -17.3% |
| Q3 2017 | $2,459,000 | -1.7% | 79,071 | 0.0% | 0.38% | -25.3% |
| Q2 2017 | $2,502,000 | +39.7% | 79,071 | 0.0% | 0.50% | +38.7% |
| Q1 2017 | $1,791,000 | +50.8% | 79,071 | +45.3% | 0.36% | +35.6% |
| Q4 2016 | $1,188,000 | -17.2% | 54,432 | 0.0% | 0.27% | -51.0% |
| Q3 2016 | $1,435,000 | +44.8% | 54,432 | +8.5% | 0.54% | +27.6% |
| Q2 2016 | $991,000 | – | 50,178 | – | 0.43% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Conrad N. Hilton Foundation | 63,481 | $7,847,000 | 100.00% |
| CPMG Inc | 2,896,901 | $358,115,000 | 55.16% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 140,000 | $17,307,000 | 26.62% |
| Corriente Advisors, LLC | 525,000 | $64,901,000 | 15.45% |
| DUMAC, INC. | 76,050 | $9,401,000 | 7.33% |
| MADDEN SECURITIES Corp | 35,152 | $4,345,000 | 2.80% |
| Biondo Investment Advisors, LLC | 113,692 | $14,055,000 | 2.69% |
| Duquesne Family Office | 749,897 | $92,702,000 | 2.50% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,754,000 | 2.44% |
| Integral Health Asset Management, LLC | 50,000 | $6,181,000 | 1.84% |